Republican lawmakers are raising concerns that companies may face environmental barriers to manufacturing more pharmaceuticals and active pharmaceutical ingredients in the US, as the idea of onshoring gains popularity as an option for relieving generic drug shortages.
The 6 February House Ways and Means Committee hearing on drug shortages spent ample time discussing how the US could...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?